Vol. 21/No. 20

Kidney cancer experts emphasize the importance of risk stratification for guiding treatment decisions and discussed the clinical trials that have shaped the frontline treatment recommendations from the National Comprehensive Cancer Network for advanced clear cell RCC.

p53 presents a significant challenge for investigators, and the field is littered with clinical trial failures and abandoned drug development programs.

New approaches for treating patients with HER2-positive metastatic breast cancer are showing signs of efficacy against brain metastases, generating excitement about the potential to make critical advances and sparking questions about optimal sequencing.

Oncology practices across the United States have rapidly increased telehealth use in 2020 to mitigate the risk of coronavirus disease 2019 (COVID-19) to patients with cancer who are at particular risk of complications.

The impact of COVID-19 has been felt deeply by community-based oncologists.

Data from a subgroup analysis of the phase 2 GRIFFIN study demonstrated that adding daratumumab to lenalidomide, bortezomib, and dexamethasone improved depth of response, stringent complete response, and minimal residual disease negativity, in Black patients with newly diagnosed multiple myeloma.

In less than 10 years, immune checkpoint inhibitors (ICIs) have dramatically altered the treatment landscape for patients with metastatic melanoma, helping to drive an improvement in 5-year survival rates from historical levels of less than 10% to more than 50% with some regimens.

Todd Bauer, MD, discusses how the highly specific nature of selpercatinib leads to greater tolerability than multityrosine kinase inhibitors and its frontline potential.

The fundamental objectivity of major scientifically oriented public health agencies has been called into question, while the issue of what constitutes sufficient evidence for a therapeutic strategy to be considered “standard” is also being challenged.